VYM Vanguard High Dividend Yield ETF
- 127.920
- -0.280-0.22%
The Covid Era Tech Promises To Reinvent Cancer Treatment
A Closer Look at Walmart's Options Market Dynamics
East Coast Dockworkers Strike: How Labor Dispute Impacts Economy, Logistics Companies
BofA's Top 10 Ideas for the Fourth Quarter
Watch These Stocks as Union Pushes Pick up
In-Depth Analysis: Walmart Versus Competitors In Consumer Staples Distribution & Retail Industry
Clorox Entering FY25 as 'a Different Company' -- Analyst
Dockworkers Strike: Will It Impact Your Holiday Shopping?
J&J Submits Supplemental BLA for Darzalex Faspro to FDA
Will PepsiCo Announce a Major Strategy Change When It Reports Earnings Next Week?
Procter & Gamble Analyst Ratings
Home Depot Analyst Ratings
Johnson & Johnson Analyst Ratings
Today's Pre-Market Movers and Top Ratings | STLA, CVS, NIO and More
Robinhood To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Monday
Stocks With the Highest Consensus of Expected ROE Growth, Goldman Sachs Says
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
J&J, Legend Report Carvykti Cut Death Risk by 45% in Multiple Myeloma Study
J&J Releases Encouraging Data on Talvey Combination Therapies
Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After...